Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Scientists have identified the Plvap gene as a key regulator of metabolism during fasting. Disabling it in mice prevented the ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

BRINP2-related peptide, or BRP, is a naturally occurring molecule that can suppress appetite and promote weight loss in mice ...

The end of compounded versions of weight-loss drugs is near, leaving patients scrambling for alternatives. Some “copycat” ...

In an increasingly competitive telehealth weight loss market, thoughtful and transparent branding is critical.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.

Injectable drugs like Ozempic and Wegovy may be new to most of the world, but the science behind them are familiar to those in the health field.